Percutaneous tibial nerve stimulation (PTNS): A literature-based assessment

  • Scott A. MacDiarmidEmail author
  • David R. Staskin


An estimated 34 million adults in the United States have an overactive bladder, which has a significant impact on health and quality of life and significant overall financial impact on the health care delivery system. Current treatment alternatives include behavioral modifications, pelvic floor therapy, medications, sacral nerve stimulation, intravesical injection, and surgery. A recent addition to the urologist’s armamentarium of care is percutaneous tibial nerve stimulation. This article reviews a variety of sources that present current thinking about percutaneous tibial nerve stimulation, its clinical use, and its place in the continuum of care.


Overactive Bladder Tolterodine Sacral Nerve Stimulation Lower Urinary Tract Dysfunction Antimuscarinic Agent 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References and Recommended Reading

  1. 1.
    Abrams P, Cardozo L, Fall M, et al.: The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003, 61:37–49.PubMedCrossRefGoogle Scholar
  2. 2.
    Milsom I, Abrams P, Cardozo L, et al.: How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001, 87:760–766. (Published erratum appears in BJU Int 2001, 88:807.)PubMedCrossRefGoogle Scholar
  3. 3.
    Milsom I, Irwin DE: A cross-sectional, population-based, multinational study of the prevalence of overactive bladder and lower urinary tract symptoms: results from the EPIC study. Eur Urol Suppl 2007, 6:4–9.CrossRefGoogle Scholar
  4. 4.
    Stewart WF, Van Rooyen JB, Cundiff GW, et al.: Prevalence and burden of overactive bladder in the United States. World J Urol 1999, 44:55–56.Google Scholar
  5. 5.
    Abrams P, Kelleher CJ, Kerr LA, Rogers RG: Overactive bladder significantly affects quality of life. Am J Manag Care 2000, 6:S580–S590.PubMedGoogle Scholar
  6. 6.
    Basra RK, Wagg A, Chapple C, et al.: A review of adherence to drug therapy in patients with overactive bladder. BJU Int 2008, 102:774–779.PubMedCrossRefGoogle Scholar
  7. 7.
    Wein AJ, Rackley RR: Overactive bladder: a better understanding of pathophysiology, diagnosis and management. J Urol 2006, 175:S5.PubMedCrossRefGoogle Scholar
  8. 8.
    Alhasso AA, McKinlay J, Patrick K, Stewart L: Anticholinergic drugs versus non-drug active therapies for overactive bladder in adults. Cochrane Database Syst Rev 2006, 18:CD003103.Google Scholar
  9. 9.
    van der Pal F, Heesakkers JPFA, Bemelmans BLH: Current opinion on the working mechanism of neuromodulation in the treatment of lower urinary tract dysfunction. Curr Opin Urol 2006, 16:261–267.PubMedCrossRefGoogle Scholar
  10. 10.
    Cooperberg MR, Stoller ML: Percutaneous neuromodulation. Urol Clin North Am 2005, 32:71–78.PubMedCrossRefGoogle Scholar
  11. 11.
    Peters KM, MacDiarmid SA, Siegel SW, et al.: A randomized multicenter study comparing percutaneous tibial nerve stimulation with pharmaceutical therapy for the treatment of overactive bladder (OrBIT study) [abstract]. J Urol 2008, 179:4.Google Scholar
  12. 12.
    Govier FE, Litwiller S, Nitti V, et al.: Percutaneous afferent neuromodulation for the refractory overactive bladder: results of a multi-center study. J Urol 2001, 165:1193–1198.PubMedCrossRefGoogle Scholar
  13. 13.
    van Balken MR, Vandoninck V, Gisolf KWH, et al.: Posterior tibial nerve stimulation as neuromodulative treatment of lower urinary tract dysfunction. J Urol 2001, 166:914–918.PubMedCrossRefGoogle Scholar
  14. 14.
    van der Pal F, van Balken MR, Heesakkers JPFA, et al.: Correlation between quality of life and voiding variables in patients treated with percutaneous tibial nerve stimulation. BJU Int 2006, 97:113–116.PubMedCrossRefGoogle Scholar
  15. 15.
    van der Pal F, van Balken MR, Heesakkers JP, et al.: Percutaneous tibial nerve stimulation in the treatment of refractory overactive bladder syndrome: is maintenance treatment necessary? BJU Int 2006, 97:113–116.PubMedCrossRefGoogle Scholar
  16. 16.
    Klingler HC, Pycha A, Schmidbauer J, Marberger M: Use of peripheral neuromodulation of the S3 region for treatment of detrusor overactivity: a urodynamic-based study. Urology 2000, 56:766–771.PubMedCrossRefGoogle Scholar
  17. 17.
    Vandoninck V, van Balken MR, Finazzi-Agró E, et al.: Percutaneous tibial nerve stimulation in the treatment of overactive bladder: urodynamic data. Neurourol Urodyn 2003, 22:227–232.PubMedCrossRefGoogle Scholar
  18. 18.
    Ruiz CB, Outeiriño PXM, Martinez PC, et al.: Peripheral afferent nerve stimulation for treatment of lower urinary tract irritative symptoms. Eur Urol 2004, 45:65–69.CrossRefGoogle Scholar
  19. 19.
    Kim SW, Paick JS, Ku JH: Percutaneous posterior tibial nerve stimulation in patients with chronic pelvic pain: a preliminary study. Urol Int 2007, 78:58–62.PubMedCrossRefGoogle Scholar
  20. 20.
    MacDiarmid SA: Overactive bladder: improving the efficacy of anticholinergics by dose escalation. Curr Urol Rep 2003, 4:446–451.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group, LLC 2009

Authors and Affiliations

  1. 1.Alliance Urology SpecialistsBladder Control and Pelvic Pain CenterGreensboroUSA

Personalised recommendations